ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT01903993
Brief Title: A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"

First Submitted : July 17, 2013
First Submitted that Met QC Criteria : July 17, 2013
First Posted : July 19, 2013 (Estimate)

Results First Submitted : November 16, 2016
Results First Submitted that Met QC Criteria : April 24, 2017
Results First Posted : May 23, 2017

Certification/Extension First Submitted : June 15, 2016
Certification/Extension First Submitted that Met QC Criteria : June 16, 2016
Certification/Extension First Posted : June 20, 2016 (Estimate)

Last Update Submitted that Met QC Criteria : September 17, 2018
Last Update Posted : October 16, 2018